The unique serine/threonine phosphorylation domain in YES1 regulates cell cycle progression, and this gene has high expression in a variety of tumors, including non-small cell lung cancer (40), gastric cancer (41), ovarian cancer (42), and breast cancer (43), and is therefore considered a novel therapeutic target and biomarker for cancer (44). Here, YES1 is linked to ovarian carcinoma.